

Robert B Raffa

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3092666/robert-b-raffa-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

222
papers

6,860
citations

40
h-index

74
g-index

230
ext. papers

7,634
ext. citations

3.3
avg, IF

6.01
L-index

#	Paper	IF	Citations
222	Treating Apnea of Prematurity.. <i>Cureus</i> , 2022 , 14, e21783	1.2	
221	Benzodiazepines: Thinking outside the black box. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 554-559	2.2	6
220	The problem of postoperative respiratory depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 1220-1225	2.2	0
219	Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 861-866	2.2	2
218	Benefit-Risk Analysis of Buprenorphine for Pain Management. <i>Journal of Pain Research</i> , 2021 , 14, 1359-1369		3
217	Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 1501-1504	2.2	3
216	Kratom use in the United States: a diverse and complex profile. <i>Addiction</i> , 2021 , 116, 202-203	4.6	9
215	Potential neurological manifestations of COVID-19: a narrative review. <i>Postgraduate Medicine</i> , 2021 , 1-11	3.7	10
214	The Zika virus: Lurking behind the COVID-19 pandemic?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 267-276	2.2	5
213	Bone fractures during the time of coronavirus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 543-546	2.2	3
212	The Challenge of Polysubstance Use Overdose. <i>Open Journal of Social Sciences</i> , 2021 , 09, 529-542	0.2	
211	Neuronal Effects of Listening to Entrainment Music Versus Preferred Music in Patients With Chronic Cancer Pain as Measured via EEG and LORETA Imaging. <i>Frontiers in Psychology</i> , 2021 , 12, 588788 ^{3,4}		2
210	Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 1505-1508	2.2	4
209	Pharmacologic agents directed at the treatment of pain associated with maladaptive neuronal plasticity. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-12	4	4
208	The conundrum of polysubstance overdose. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 1189-1193		0
207	Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020 , 45, 892-903	2.2	33
206	Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache. <i>Drugs of Today</i> , 2020 , 56, 5-19	2.5	5

205	Commentary: New Complications Make Treatment of Opioid Overdose Challenging. <i>Pharmacology & Pharmacy</i> , 2020 , 11, 362-372	0.3	
204	Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. <i>Pain Medicine</i> , 2020 , 21, 714-723	2.8	22
203	Developments in combined analgesic regimens for improved safety in postoperative pain management. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 981-990	4.3	1
202	e-Cigarettes for smoking cessation: Do they deliver?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 650-655	2.2	6
201	Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 361-371	2.2	5
200	Discovery of "folded DNA" structures in human cells: Potential drug targets. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 125-128	2.2	2
199	<i></i>Commentary</i>: Benzodiazepine (BZD) and Related BZD-Receptor Agonists: Basic Science Reasons to Limit to Four Weeks or Less. <i>Pharmacology & Pharmacy</i> , 2019 , 10, 357-364	0.3	1
198	Treating pain in patients with dementia and the possible concomitant relief of symptoms of agitation. <i>Pain Management</i> , 2019 , 9, 569-582	2.3	2
197	Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain. <i>Journal of Pain Research</i> , 2019 , 12, 3299-3317	2.9	14
196	Sunscreen bans: Coral reefs and skin cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 134-139	2.3	27
195	Knowledge, Attitude and Practice Survey of Prescribing Opioids for Chronic Noncancer Pain in Taiwan-Comparison of Pain and Non-Pain Physicians. <i>Pain Medicine</i> , 2019 , 20, 2397-2410	2.8	5
194	Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain. <i>Pain and Therapy</i> , 2018 , 7, 37-57	3.6	11
193	Abuse-deterrent opioids: an update on current approaches and considerations. <i>Current Medical Research and Opinion</i> , 2018 , 34, 711-723	2.5	25
192	Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 443-449	2.2	6
191	Curcumin in turmeric: Basic and clinical evidence for a potential role in analgesia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 460-466	2.2	25
190	Nature's first "atypical opioids": Kratom and mitragynines. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 437-441	2.2	21
189	The role and mechanism of action of menthol in topical analgesic products. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 313-319	2.2	22
188	The fentanyl family: A distinguished medical history tainted by abuse. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 154-158	2.2	20

187	Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. <i>Journal of Pain Research</i> , 2018 , 11, 301-311	2.9	9
186	Driving under the influence of opioids: What prescribers should know. <i>Journal of Opioid Management</i> , 2018 , 14, 415-427	0.8	4
185	A Guide for Cancer Pain Management in Latin America. <i>Journal of Cancer Research Updates</i> , 2018 , 6, 81-96		
184	The rapid-onset antidepressant effect of ketamine: More surprises?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 308-311	2.2	2
183	Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin. <i>Postgraduate Medicine</i> , 2018 , 130, 1-8	3.7	68
182	Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. <i>Clinical Drug Investigation</i> , 2018 , 38, 259-268	3.2	19
181	Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model. <i>Pharmacology Research and Perspectives</i> , 2018 , 6, e00444	3.1	7
180	Designing safer analgesics: a focus on opioid receptor pathways. <i>Expert Opinion on Drug Discovery</i> , 2018 , 13, 965-972	6.2	21
179	Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'. <i>Advances in Therapy</i> , 2018 , 35, 1471-1484	4.1	37
178	What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders. <i>Expert Opinion on Drug Delivery</i> , 2018 , 15, 567-576	8	2
177	What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 147-154	2.2	45
176	Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 467-477	3.5	18
175	Considering tapentadol as a first-line analgesic: 14 questions. <i>Pain Management</i> , 2017 , 7, 331-339	2.3	7
174	The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review. <i>Postgraduate Medicine</i> , 2017 , 129, 698-708	3.7	
173	The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review. <i>Pain and Therapy</i> , 2017 , 6, 1-16	3.6	23
172	Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan: A cross-sectional study. <i>Journal of the Formosan Medical Association</i> , 2017 , 116, 257-265	3.2	11
171	Safety of buprenorphine transdermal system in the management of pain in older adults. <i>Postgraduate Medicine</i> , 2017 , 129, 92-101	3.7	13
170	The "Darknet": The new street for street drugs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 790-792	2.2	12

169	Peripherally acting Epioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. <i>Patient Preference and Adherence</i> , 2017 , 11, 107-119 ^{2.4}	2.4	25
168	Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system. <i>Journal of Pain Research</i> , 2017 , 10, 1255-1263	2.9	9
167	Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies. <i>Drug Delivery and Translational Research</i> , 2017 , 7, 1-10	6.2	15
166	Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 8-17	2.2	31
165	A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression. <i>Pain Practice</i> , 2016 , 16, 473-83 ³		6
164	The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 592-593 ^{2.2}	2.2	7
163	Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 371-82	2.2	56
162	Perspectives on Intravenous Oxycodone for Control of Postoperative Pain. <i>Pain Practice</i> , 2016 , 16, 924-34		15
161	Evolution to low-dose NSAID therapy. <i>Pain Management</i> , 2016 , 6, 175-89	2.3	5
160	Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering). <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2016 , 66, 310-7	0.2	4
159	A Guide for Pain Management in Developing Nations: The Diagnosis and Assessment of Pain in Cancer Patients. <i>Journal of Cancer Research Updates</i> , 2016 , 5, 29-44	1	
158	Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology. <i>Journal of Pain Research</i> , 2016 , 9, 909-916	2.9	10
157	Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials. <i>Pain Practice</i> , 2016 , 16, 345-58	3	15
156	Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015 , 40, 615-9	2.2	8
155	The role of abuse-deterrent formulations in countering opioid misuse and abuse. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015 , 40, 629-34	2.2	5
154	Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. <i>Journal of Pain Research</i> , 2015 , 8, 229-38	2.9	19
153	The unsolved case of "bone-impairing analgesics": the endocrine effects of opioids on bone metabolism. <i>Therapeutics and Clinical Risk Management</i> , 2015 , 11, 515-23	2.9	41
152	Clostridium difficile infection: A brief update on emerging therapies. <i>American Journal of Health-System Pharmacy</i> , 2015 , 72, 1007-12	2.2	20

151	Is levorphanol a better option than methadone?. <i>Pain Medicine</i> , 2015 , 16, 1673-9	2.8	17
150	Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015 , 40, 125-30	2.2	18
149	Stereochemistry and neuropharmacology of a 'bath salt' cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates. <i>Neuropharmacology</i> , 2015 , 91, 109-16	5.5	18
148	Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management?. <i>Agri Dergisi</i> , 2015 , 27, 1-11	0.5	
147	Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. <i>European Journal of Pain</i> , 2014 , 18, 1148-56	3.7	12
146	On subclasses of opioid analgesics. <i>Current Medical Research and Opinion</i> , 2014 , 30, 2579-84	2.5	13
145	Acetaminophen (paracetamol) oral absorption and clinical influences. <i>Pain Practice</i> , 2014 , 14, 668-77	3	34
144	Treating acute pain in light of the chronification of pain. <i>Pain Management Nursing</i> , 2014 , 15, 380-90	2.5	30
143	Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo. <i>Neuropharmacology</i> , 2014 , 79, 590-5	5.5	40
142	Combining opioid and adrenergic mechanisms for chronic pain. <i>Postgraduate Medicine</i> , 2014 , 126, 98-114	3.7	14
141	Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014 , 39, 25-37	2.2	46
140	A modern analgesics pain 'pyramid'. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014 , 39, 4-6	2.2	23
139	Opioid formulations with sequestered naltrexone: a perspective review. <i>Therapeutic Advances in Drug Safety</i> , 2014 , 5, 129-37	3.5	2
138	Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 181-90	4.1	5
137	Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness. <i>Sleep Disorders</i> , 2014 , 2014, 5271-9	1.9	4
136	The clinical analgesic efficacy of buprenorphine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014 , 39, 577-83	2.2	50
135	Short Overview of Mitragynines 2014 , 9-22		
134	A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. <i>Pain Practice</i> , 2013 , 13, 239-52	3	54

133	The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013 , 38, 350-9	2.2	22
132	Cocaine synergism with μ agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition. <i>Drug and Alcohol Dependence</i> , 2013 , 129, 226-31	4.9	6
131	Opioid receptor types involved in the development of nicotine physical dependence in an invertebrate (Planaria) model. <i>Pharmacology Biochemistry and Behavior</i> , 2013 , 112, 9-14	3.9	6
130	Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013 , 38, 265-8	2.2	7
129	Sucrose produces withdrawal and dopamine-sensitive reinforcing effects in planarians. <i>Physiology and Behavior</i> , 2013 , 112-113, 8-13	3.5	15
128	Tapentadol extended release for chronic pain patients. <i>Advances in Therapy</i> , 2013 , 30, 14-27	4.1	14
127	Opioid antagonists for pain. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 517-25	5.9	10
126	Orally active opioid compounds from a non-poppy source. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 4840-8	2.2	22
125	Vitamin D and type 2 diabetes mellitus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013 , 38, 81-4	2.2	5
124	Opioid-induced hyperalgesia: is it clinically relevant for the treatment of pain patients?. <i>Pain Management Nursing</i> , 2013 , 14, e67-83	2.5	26
123	Tramadol/Paracetamol fixed-dose combination for chronic pain management in family practice: a clinical review. <i>ISRN Family Medicine</i> , 2013 , 2013, 638469		5
122	Multi-mechanistic analgesia for opioid-induced hyperalgesia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012 , 37, 125-7	2.2	10
121	CB μ -independent mechanisms of μ HCV, AM251 and SR141716 (rimonabant). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012 , 37, 260-5	2.2	13
120	Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulations. <i>Pain Practice</i> , 2012 , 12, 159-73	3	25
119	A randomized, double-blind comparison shows the addition of oxygenated glycerol triesters to topical mentholated cream for the treatment of acute musculoskeletal pain demonstrates incremental benefit over time. <i>Pain Practice</i> , 2012 , 12, 610-9	3	5
118	Intracerebroventricular opioids for intractable pain. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 34-41	3.8	17
117	'Null method' determination of drug biophase concentration. <i>Pharmaceutical Research</i> , 2012 , 29, 637-42	4.5	1
116	Mechanistic and functional differentiation of tapentadol and tramadol. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1437-49	4	107

115	Mephedrone ("bath salt") pharmacology: insights from invertebrates. <i>Neuroscience</i> , 2012 , 208, 79-84	3.9	31
114	Fixed-dose combinations for emerging treatment of pain. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1261-70	4	16
113	QTc interval prolongation by d-propoxyphene: what about other analgesics?. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1397-409	4	18
112	Pain treatment in arthritis-related pain: beyond NSAIDs. <i>Open Rheumatology Journal</i> , 2012 , 6, 320-30	0.2	74
111	Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. <i>Journal of Pain Research</i> , 2012 , 5, 327-46	2.9	23
110	The evolving understanding of the analgesic mechanism of action of flupirtine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012 , 37, 4-6	2.2	20
109	Designing opioids that deter abuse. <i>Pain Research and Treatment</i> , 2012 , 2012, 282981	1.9	12
108	Extended-release formulations of tramadol in the treatment of chronic pain. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1757-68	4	18
107	007. A randomized, double-blind comparison of the addition of oxygenated glycerol triesters to topical mentholated cream for the treatment of acute musculoskeletal pain. <i>European Journal of Pain Supplements</i> , 2011 , 5, 509-510		
106	008. Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. <i>European Journal of Pain Supplements</i> , 2011 , 5, 510-510		
105	009. Safe use of fluoroquinolones: A focus on limiting CNS and peripheral neuropathy adverse events. <i>European Journal of Pain Supplements</i> , 2011 , 5, 510-510		
104	Nicotine behavioral pharmacology: clues from planarians. <i>Drug and Alcohol Dependence</i> , 2011 , 118, 274-9	4.9	41
103	Naltrexone extended-release injection: an option for the management of opioid abuse. <i>Substance Abuse and Rehabilitation</i> , 2011 , 2, 219-26	5.5	3
102	A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog'). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011 , 36, 257-9	2.2	28
101	Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011 , 36, 283-98	2.2	3
100	Cancer 'survivor-care': I. the α 7 nAChR as potential target for chemotherapy-related cognitive impairment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011 , 36, 437-45	2.2	7
99	Glutamate and aspartate measurements in individual planaria by rapid capillary electrophoresis. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011 , 63, 119-22	1.7	23
98	Potential insight for drug discovery from high fidelity receptor-mediated transduction mechanisms in insects. <i>Expert Opinion on Drug Discovery</i> , 2011 , 6, 1091-1101	6.2	

97	Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. <i>Psychopharmacology</i> , 2011 , 217, 539-48	4.7	35
96	Adolescent drug use: altered dopamine feedback control. <i>FASEB Journal</i> , 2011 , 25, 1083.8	0.9	
95	Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010 , 35, 1-9	2.2	21
94	Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010 , 35, 249-55	2.2	18
93	What do we (not) know about how paracetamol (acetaminophen) works?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010 , 35, 617-38	2.2	74
92	Imaging as a means of studying chemotherapy-related cognitive impairment. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 678, 70-6	3.6	5
91	Opioid formulations designed to resist/deter abuse. <i>Drugs</i> , 2010 , 70, 1657-75	12.1	73
90	European perspectives on upcoming analgesics: What do they have that we don't know and what do they think about them?. <i>Techniques in Regional Anesthesia and Pain Management</i> , 2010 , 14, 86-98		
89	5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians. <i>Neuroscience Letters</i> , 2010 , 484, 113-7	3.3	5
88	Diselenium, instead of disulfide, bonded analogs of conotoxins: novel synthesis and pharmacotherapeutic potential. <i>Life Sciences</i> , 2010 , 87, 451-6	6.8	9
87	On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data. <i>Drug and Alcohol Dependence</i> , 2010 , 109, 126-9	4.9	10
86	The determination and application of fixed-dose analgesic combinations for treating multimodal pain. <i>Journal of Pain</i> , 2010 , 11, 701-9	5.2	61
85	First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. <i>Behavioural Pharmacology</i> , 2010 , 21, 301-13	2.4	19
84	The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. <i>Pharmacology & Therapeutics</i> , 2010 , 127, 165-74	13.9	44
83	Topiramate-antagonism of L-glutamate-induced paroxysms in planarians. <i>European Journal of Pharmacology</i> , 2010 , 649, 150-3	5.3	17
82	Current knowledge of buprenorphine and its unique pharmacological profile. <i>Pain Practice</i> , 2010 , 10, 428-50	3	198
81	Oxycodone combinations for pain relief. <i>Drugs of Today</i> , 2010 , 46, 379-98	2.5	20
80	Future directions. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 678, 165-7	3.6	

79	Short introduction and history. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 678, 1-10	3.6	3
78	Chemotherapy-related visual system toxicity. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 678, 113-8	3.6	3
77	Chemo fog: cancer chemotherapy-related cognitive impairment. Preface. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 678, vii-viii	3.6	5
76	Patient's perspective. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 678, 11-2	3.6	
75	Considerations on the use of oxymorphone in geriatric patients. <i>Expert Opinion on Drug Safety</i> , 2009 , 8, 603-13	4.1	12
74	Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. <i>Pharmacology Biochemistry and Behavior</i> , 2009 , 93, 363-7	3.9	36
73	The M5 muscarinic receptor as possible target for treatment of drug abuse. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009 , 34, 623-9	2.2	24
72	Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. <i>British Journal of Pharmacology</i> , 2009 , 157, 831-43	8.6	34
71	Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). <i>Pain Practice</i> , 2008 , 8, 287-313	3	577
70	Basic pharmacology relevant to drug abuse assessment: tramadol as example. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008 , 33, 101-8	2.2	68
69	The kappa-opioid receptor antagonist nor-BNI inhibits cocaine and amphetamine, but not cannabinoid (WIN 52212-2), abstinence-induced withdrawal in planarians: an instance of 'pharmacologic congruence'. <i>Brain Research</i> , 2008 , 1193, 51-6	3.7	14
68	The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. <i>European Journal of Pharmacology</i> , 2008 , 584, 278-84	5.3	23
67	Nociceptin attenuates methamphetamine abstinence-induced withdrawal-like behavior in planarians. <i>Neuropeptides</i> , 2008 , 42, 229-37	3.3	8
66	Thermodynamics of Protein-Ligand Interactions 2008 , 51		
65	Withdrawal-like behavior in planarians is dependent on drug exposure duration. <i>Neuroscience Letters</i> , 2008 , 439, 84-8	3.3	18
64	Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008 , 325, 500-6	4.7	38
63	Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. <i>Psychopharmacology</i> , 2008 , 199, 527-38	4.7	56
62	Agmatine: identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians. <i>Synapse</i> , 2008 , 62, 927-34	2.4	14

61	PTX-insensitive Gz transduction pathway contributes to buprenorphine-induced supraspinal, but not spinal, antinociception. <i>FASEB Journal</i> , 2008 , 22, 1125-10	0.9	
60	Acquisition, retention, or spontaneous recovery learning is impaired in mice by weekly treatments of 5-fluorouracil or methotrexate. <i>FASEB Journal</i> , 2008 , 22, 614-614	0.9	
59	Looking beyond the administered drug: metabolites of opioid analgesics. <i>Journal of Family Practice</i> , 2008 , 57, S25-32	0.2	2
58	The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007 , 32, 209-31	2.2	70
57	Nonlinear isobologram and superadditive withdrawal from cocaine: cannabinoid combinations in planarians. <i>European Journal of Pharmacology</i> , 2007 , 556, 89-90	5.3	9
56	Flumazenil-sensitive dose-related physical dependence in planarians produced by two benzodiazepine and one non-benzodiazepine benzodiazepine-receptor agonists. <i>European Journal of Pharmacology</i> , 2007 , 564, 88-93	5.3	14
55	An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). <i>Pharmacology Biochemistry and Behavior</i> , 2007 , 86, 499-504	3.9	31
54	Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. <i>Acute Pain</i> , 2007 , 9, 145-152		34
53	Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria. <i>European Journal of Pharmacology</i> , 2006 , 540, 200-1	5.3	6
52	Modified 'Joyce model' of opioid dependence/withdrawal. <i>European Journal of Pharmacology</i> , 2006 , 551, 54-7	5.3	1
51	A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. <i>Brain Research</i> , 2006 , 1099, 82-7	3.7	24
50	Subadditive withdrawal from cocaine/kappa-opioid agonist combinations in Planaria. <i>Brain Research</i> , 2006 , 1114, 31-5	3.7	15
49	Measurement of glutamate and aspartate in Planaria. <i>Journal of Pharmacological and Toxicological Methods</i> , 2006 , 53, 291-5	1.7	33
48	Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006 , 31, 129-38	2.2	47
47	Pharmacological aspects of successful long-term analgesia. <i>Clinical Rheumatology</i> , 2006 , 25 Suppl 1, S9-15	3.9	39
46	Amphetamine-induced increase in planarian locomotor activity and block by UV light. <i>Brain Research</i> , 2005 , 1031, 138-40	3.7	20
45	Description and quantification of cocaine withdrawal signs in Planaria. <i>Brain Research</i> , 2005 , 1032, 200-23	3.7	33
44	A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in Planaria. <i>Journal of Pharmacological and Toxicological Methods</i> , 2005 , 51, 73-6	1.7	33

43	Bacterial communication ("quorum sensing") via ligands and receptors: a novel pharmacologic target for the design of antibiotic drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 312, 417-23	4.7	94
42	Buprenorphine □The Unique Opioid Analgesic 2005 ,		13
41	Protonation effect on drug affinity. <i>European Journal of Pharmacology</i> , 2004 , 483, 323-4	5.3	6
40	Opioid receptors and acetaminophen (paracetamol). <i>European Journal of Pharmacology</i> , 2004 , 503, 209-10	5.3	29
39	Cocaine and kappa-opioid withdrawal in Planaria blocked by D-, but not L-, glucose. <i>Brain Research</i> , 2004 , 1018, 181-5	3.7	17
38	Isothermal titration calorimetric study of RNase-A kinetics (cCMP → 3'-CMP) involving end-product inhibition. <i>Pharmaceutical Research</i> , 2004 , 21, 1642-7	4.5	9
37	Disruption of a drug-induced choice behavior by UV light. <i>Behavioural Pharmacology</i> , 2003 , 14, 569-71	2.4	13
36	Critical Evaluation of Reported Plant Sources of Possibly Novel Analgesic Compounds. <i>Reviews in Analgesia</i> , 2003 , 7, 97-117		1
35	Mechanism of action of analgesics used to treat osteoarthritis pain. <i>Rheumatic Disease Clinics of North America</i> , 2003 , 29, 733-45	2.4	6
34	kappa-Opioid withdrawal in Planaria. <i>Neuroscience Letters</i> , 2003 , 349, 139-42	3.3	28
33	Combination strategies for pain management. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 1697-708	4	52
32	Experimental Approaches to Determine the Thermodynamics of Protein-Ligand Interactions. <i>Methods and Principles in Medicinal Chemistry</i> , 2003 , 51-71	0.4	
31	Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 307, 699-704	4.7	33
30	Toward RNase inhibitors: thermodynamics of 2'-CMP/RNase-A binding in multi-ion buffer. <i>Biochemical Pharmacology</i> , 2002 , 63, 1937-9	6	5
29	Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002 , 27, 99-106	2.2	28
28	Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002 , 27, 169-83	2.2	23
27	Toward the design of ribonuclease (RNase) inhibitors: ion effects on the thermodynamics of binding of 2'-CMP to RNase A. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 301, 925-9	4.7	7
26	Antihistamines as analgesics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001 , 26, 81-5	2.2	44

25	Pharmacology of oral combination analgesics: rational therapy for pain. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001 , 26, 257-64	2.2	194
24	Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. <i>European Journal of Pharmacology</i> , 2001 , 412, R1-2	5.3	18
23	Cocaine withdrawal in Planaria. <i>European Journal of Pharmacology</i> , 2001 , 430, 143-5	5.3	58
22	Quantitative assessment of dopamine D2 antagonist activity using invertebrate (Planaria) locomotion as a functional endpoint. <i>Journal of Pharmacological and Toxicological Methods</i> , 2001 , 45, 223-6	1.7	65
21	Could a common biochemical mechanism underlie addictions?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000 , 25, 11-20	2.2	23
20	Energy-dependent UV light-induced disruption of (-)-sulpiride antagonism of dopamine. <i>European Journal of Pharmacology</i> , 2000 , 406, R11-2	5.3	23
19	Discovery of "self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2000 , 295, 291-4	4.7	52
18	Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. <i>Brain Research</i> , 1999 , 831, 55-63	3.7	75
17	Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats. <i>Pain</i> , 1999 , 82, 65-72	8	94
16	Response surface analysis of synergism between morphine and clonidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999 , 289, 8-13	4.7	54
15	Orphanin-FQ/nociceptin: lack of anti nociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. <i>European Journal of Pain</i> , 1998 , 2, 267-78	3.7	23
14	Efficient designs for studying synergistic drug combinations. <i>Life Sciences</i> , 1997 , 61, PL 417-25	6.8	104
13	Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. <i>Life Sciences</i> , 1996 , 58, PL 23-8	6.8	54
12	Lack of binding of acetaminophen to 5-HT receptor or uptake sites (or eleven other binding/uptake assays). <i>Life Sciences</i> , 1996 , 59, PL37-40	6.8	29
11	Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. <i>European Journal of Pharmacology</i> , 1996 , 316, 369-72	5.3	61
10	The 'glibenclamide-shift' of centrally-acting antinociceptive agents in mice. <i>Brain Research</i> , 1995 , 677, 277-82	3.7	44
9	Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995 , 274, 1263-70	4.7	207
8	Topiramate: preclinical evaluation of structurally novel anticonvulsant. <i>Epilepsia</i> , 1994 , 35, 450-60	6.4	297

7	G-protein antisense oligodeoxyribonucleotides and mu-opioid supraspinal antinociception. <i>European Journal of Pharmacology</i> , 1994 , 258, R5-7	5.3	62
6	Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1993 , 267, 331-40	4.7	273
5	Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1992 , 260, 275-85	4.7	688
4	Principles in General Pharmacology 1988 ,		17
3	Ultraviolet light-induced photorelaxation of agonist-contracted rabbit aorta: Further characterization and the estimation of drug-receptor rate constants. <i>Drug Development Research</i> , 1985 , 5, 359-369	5.1	6
2	On the criteria for classifying opiate agonists in rats. <i>Journal of Pharmacy and Pharmacology</i> , 1982 , 34, 525-6	4.8	12
1	Tolerance and cross-tolerance studies with morphine and ethylketocyclazocine. <i>Journal of Pharmacy and Pharmacology</i> , 1982 , 34, 666-7	4.8	23